OS Therapies Inc
About OS Therapies Inc
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$28.8M
- Total assets
- $6.8M
- Market cap
- $79.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$28.7M
- Net income
- -$28.8M
- EPS (basic)
- $-0.98
- EPS (diluted)
- $-0.98
Balance sheet
- Total assets
- $6.8M
- Current assets
- $332.9K
- Total liabilities
- $11.9M
- Current liabilities
- $11.8M
- Shareholders’ equity
- -$6.1M
Cash flow
- Operating cash flow
- -$14.2M
- Investing cash flow
- -$466.4K
- Financing cash flow
- $9.4M
- Net cash flow
- -$5.3M
Statements via Polygon.io (SEC filings)
- Market cap
- $79.3M
- EPS (diluted)
- $-0.98
- Shares outstanding
- 46.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 1, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $28.8M.
- Trading 32% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review OS Therapies Inc.
Write a review
News about OS Therapies Inc
News & sentiment via Polygon.io
